These sources provide a comprehensive overview of Pseudoxanthoma Elasticum (PXE), a rare genetic disorder defined by the progressive mineralisation of elastic connective tissues. The condition is primarily driven by mutations in the ABCC6 gene, which lead to a deficiency in inorganic pyrophosphate, a crucial inhibitor of calcification. Patients typically experience significant complications affecting the skin, eyes, and cardiovascular system, including loss of central vision and arterial narrowing. Current medical research highlighted in the texts focuses on novel therapeutic interventions, such as TNAP inhibitors like DS-1211b, to restore phosphate balance. Furthermore, the documents emphasise the vital role of patient advocacy groups like PXE International in coordinating global research and maintaining biological repositories. Ongoing clinical trials and diagnostic advancements continue to refine the management of this multisystem disease.